Virax Biolabs Secures $5mln in Funding for 12.5mln Shares and Preferred Investment Options

Virax Biolabs Group Limited has entered into a definitive agreement to raise $5 million through the issuance of 12.5 million ordinary shares at $0.40 each and preferred investment options to purchase up to an additional 12.5 million shares at the same price. The private placement is expected to close on December 4, 2025, subject to customary closing conditions.